The activation of Vγ9Vδ2 T cells has emerged as a promising modality in cancer immunotherapy. Phosphate and phosphonate prodrugs of Vγ9Vδ2 T cell phosphoantigens have been developed as potent activators of Vγ9Vδ2 T cells that are capable of effectively facilitating lysis of a range of cancer cells in vitro. In this wor...
M. Sharif, C. M. A. Pinna, K. Rakhimova et al.· ACS Pharmacology & Translati...· 0 citations
Background Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, and emerging T cell engager (TCE) immunotherapies require predictive preclinical models that capture patient-specific tumour biology and tumour-immune interactions. Although patient-derived organoid (PDO)-immune co-culture systems s...
C. M. A. Pinna, K. Rakhimova, Jing Zhang et al.· bioRxiv· 0 citations
Integrated histopathological-molecular analysis is essential to diagnose and guide precision therapies in brain tumours. Whilst standard of care (SoC) diagnostics takes weeks, long read sequencing (LRS) on Oxford Nanopore Technology (ONT) platform and bioinformatics research tools provide rapid diagnosis within h...
Vassili Crispi, L. Ames, J. Stockton et al.· Neuro-Oncology· 0 citations
Directional cell migration requires cells to sense extracellular cues and coordinate adhesion, cytoskeletal remodelling and polarity, yet the molecular regulators that integrate these events remain incompletely defined. PTTG1-binding factor (PBF/PTTG1IP) is a transmembrane glycoprotein extensively characterised in path...
Data show that IGF2BP3 is expressed consistently in PDAC, plays a dominant role in regulation of RNA splicing and modification, and supports cancer stem cell proliferation and survival, and represents an important therapeutic target in this tumour of unmet need.
Sandra Margielewska-Davies, W. Croft, H. Pearce et al.· Oncogene· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
